Characterization of breast tissues
| Sample code | Pathology | Other information | Source | Source specimen ID | Tissue thickness |
| N1 | Normal | Absence of cancer; 35 y | Biomax | HuFPT 130 a | 5 µm |
| N2 | Normal | Absence of cancer; 44 y | Biomax | HuFPT 129 | 5 µm |
| N3 | Normal | Absence of cancer; 53 y | Biomax | HuFPT 128 | 5 µm |
| N4 | Normal | Absence of cancer | ACSR | AA-98-3672 | 5 µm |
| N5 | Normal | Absence of cancer; 56 y | BioChain | T2234086 | 5 µm |
| N6 | Normal | NAT; 50 y | BioChain | TMA core A2 | 4 µm |
| N7 | Normal | NAT; 51 y | Imgenex | IMH-1013 | 4 µm |
| N8 | Normal | NAT (cancer C4) | ACSR | AA-98-313-Q | 5 µm |
| N9 | Normal | NAT | ACSR | AA-96-193-3 | 5 µm |
| N10 | Normal | NAT | ACSR | AA-97-239-2 | 5 µm |
| N11 | Normal | NAT (cancer C2) | ACSR | AA-02-161-HH | 5 µm |
| C1 | IDC with DCIS | ER+ | ACSR | AA-97-108 B | 5 µm |
| C2 | IDC with DCIS | Lymph node +, ER−, PR-, HER2- | ACSR | AA-02-161 C | 5 µm |
| C3 | IDC | Lymph node + | ACSR | AA-98-31 A | 5 µm |
| C4 | IDC with DCIS | ER+, PR+, HER2+ | ACSR | AA-98-313 C | 5 µm |
| C5 | IDC with DCIS | Moderate to high grade | ACSR | AA-98-051-2 | 5 µm |
| C6 | IDC | Poorly differentiated | ACSR | AA-96-152-3 | 5 µm |
| C7 | IDC | TMN stage T4N3M1; 50 y | BioChain | TMA core C1 | 4 µm |
| C8 | IDC | TMN stage T2N1M0; 43 y | BioChain | TMA core C2 | 4 µm |
| C9 | IDC | TMN stage T2N3M0; 47 y | BioChain | TMA core C3 | 4 µm |
| C10 | IDC | TMN stage T2N0M0; 56 y | BioChain | TMA core C4 | 4 µm |
| C11 | IDC | TMN stage T2N2M0; 34 y | BioChain | TMA core C5 | 4 µm |
| C12 | ILC | TMN stage T2N0M0 | BioChain | TMA core D1 | 4 µm |
| C13 | ILC | TMN stage T2N0M0 | BioChain | TMA core D2 | 4 µm |
| C14 | ILC | Moderately differentiated; tumor size: 3 cm diameter; 38 y | Capital | CT2235086-3 | 5 µm |
| B1 | Hyperplasia | 41 y | BioChain | TMA core B1 | 4 µm |
| B2 | Hyperplasia | 23 y, male | BioChain | TMA core B2 | 4 µm |
| B3 | Fibroadenoma | 45 y | BioChain | TMA core B3 | 4 µm |
| B4 | Fibroadenoma | 25 y | BioChain | TMA core B4 | 4 µm |
| B5 | Fibroadenoma | 32 y | BioChain | TMA core B5 | 4 µm |
| B6 | Hyperplasia | 49 y | BioChain | TMA core A4 | 4 µm |
| Sample code | Pathology | Other information | Source | Source specimen ID | Tissue thickness |
| N1 | Normal | Absence of cancer; 35 y | Biomax | HuFPT 130 a | 5 µm |
| N2 | Normal | Absence of cancer; 44 y | Biomax | HuFPT 129 | 5 µm |
| N3 | Normal | Absence of cancer; 53 y | Biomax | HuFPT 128 | 5 µm |
| N4 | Normal | Absence of cancer | ACSR | AA-98-3672 | 5 µm |
| N5 | Normal | Absence of cancer; 56 y | BioChain | T2234086 | 5 µm |
| N6 | Normal | NAT; 50 y | BioChain | TMA core A2 | 4 µm |
| N7 | Normal | NAT; 51 y | Imgenex | IMH-1013 | 4 µm |
| N8 | Normal | NAT (cancer C4) | ACSR | AA-98-313-Q | 5 µm |
| N9 | Normal | NAT | ACSR | AA-96-193-3 | 5 µm |
| N10 | Normal | NAT | ACSR | AA-97-239-2 | 5 µm |
| N11 | Normal | NAT (cancer C2) | ACSR | AA-02-161-HH | 5 µm |
| C1 | IDC with DCIS | ER+ | ACSR | AA-97-108 B | 5 µm |
| C2 | IDC with DCIS | Lymph node +, ER−, PR-, HER2- | ACSR | AA-02-161 C | 5 µm |
| C3 | IDC | Lymph node + | ACSR | AA-98-31 A | 5 µm |
| C4 | IDC with DCIS | ER+, PR+, HER2+ | ACSR | AA-98-313 C | 5 µm |
| C5 | IDC with DCIS | Moderate to high grade | ACSR | AA-98-051-2 | 5 µm |
| C6 | IDC | Poorly differentiated | ACSR | AA-96-152-3 | 5 µm |
| C7 | IDC | TMN stage T4N3M1; 50 y | BioChain | TMA core C1 | 4 µm |
| C8 | IDC | TMN stage T2N1M0; 43 y | BioChain | TMA core C2 | 4 µm |
| C9 | IDC | TMN stage T2N3M0; 47 y | BioChain | TMA core C3 | 4 µm |
| C10 | IDC | TMN stage T2N0M0; 56 y | BioChain | TMA core C4 | 4 µm |
| C11 | IDC | TMN stage T2N2M0; 34 y | BioChain | TMA core C5 | 4 µm |
| C12 | ILC | TMN stage T2N0M0 | BioChain | TMA core D1 | 4 µm |
| C13 | ILC | TMN stage T2N0M0 | BioChain | TMA core D2 | 4 µm |
| C14 | ILC | Moderately differentiated; tumor size: 3 cm diameter; 38 y | Capital | CT2235086-3 | 5 µm |
| B1 | Hyperplasia | 41 y | BioChain | TMA core B1 | 4 µm |
| B2 | Hyperplasia | 23 y, male | BioChain | TMA core B2 | 4 µm |
| B3 | Fibroadenoma | 45 y | BioChain | TMA core B3 | 4 µm |
| B4 | Fibroadenoma | 25 y | BioChain | TMA core B4 | 4 µm |
| B5 | Fibroadenoma | 32 y | BioChain | TMA core B5 | 4 µm |
| B6 | Hyperplasia | 49 y | BioChain | TMA core A4 | 4 µm |
IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; ILC, invasive lobular carcinoma; NAT, normal adjacent to breast cancer tissue; y, years old; +, positive; −, negative; TNM, tumor (graded 0–4, based on tumor size and extension to chest wall or skin), node (lymph node metastasis, numbered as N0 [no spread to lymph nodes] or N1–3 [metastasis to lymph nodes]), metastasis (0 = no distant metastasis, 1 = distant metastasis) classification of malignant tumors; Biomax, US Biomax, Inc; ACSR, AIDS and Cancer Specimen Resource; Imgenex, Imgenex Corp.; BioChain, BioChain Institute, Inc.; TMA, TMA catalog no. Z7020010; Capital, Capital Biosciences, Inc.